The Future of Prenatal Molecular Diagnostics: Impact of the Changing Patent Landscape

January 2014Articles Pharmaceutical Patent Analyst

Recent developments in US patent law will provide both challenges and opportunities for creating effective intellectual property and commercialization strategies for prenatal molecular diagnostic methods and may ultimately influence provider and patient access to certain tests.

In Mayo v. Prometheus [1], the US Supreme Court addressed the legal standards for patent-eligible subject matter under 35 USC ยง101, with important implications for patents directed to diagnostic methods.

To view the full text, click here.